News | December 05, 2022
Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Goal of providing 12-month internship opportunities for qualified students
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Subscribe To Our Newsletter & Stay Updated
